Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
PRGN-3006 by Precigen for Refractory Acute Myeloid Leukemia: Likelihood of Approval
PRGN-3006 is under clinical development by Precigen and currently in Phase I for Refractory Acute Myeloid Leukemia. According to GlobalData,...
PRGN-3006 by Precigen for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
PRGN-3006 is under clinical development by Precigen and currently in Phase I for Relapsed Acute Myeloid Leukemia. According to GlobalData,...
PRGN-3006 by Precigen for Chronic Myelomonocytic Leukemia (CMML): Likelihood of Approval
PRGN-3006 is under clinical development by Precigen and currently in Phase I for Chronic Myelomonocytic Leukemia (CMML). According to GlobalData,...
PRGN-3006 by Precigen for Myelodysplastic Syndrome: Likelihood of Approval
PRGN-3006 is under clinical development by Precigen and currently in Phase I for Myelodysplastic Syndrome. According to GlobalData, Phase I...